Featured news from NHIVNA
HIV-related news from NAM
Maviret cures most people with HCV genotype 3 and those with cirrhosis
Liz Highleyman, 2017-10-24 12:00:00
Glecaprevir and pibrentasvir, the two drugs in the
recently approved Maviret co-formulation,
demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver cirrhosis,
according to a pair of reports presented at the 2017 AASLD Liver Meeting this
week in Washington, DC.
An integrated analysis of clinical trial data showed
that glecaprevir/pibrentasvir taken for 8 weeks cured 98% of
people without cirrhosis with hard-to-treat genotype 3, while a 12-week course cured 100% of
people with genotype 3 with cirrhosis. A related analysis showed that the
combination taken for 12 or 16 weeks cured 96% of people with compensated
cirrhosis across all genotypes.
Direct-acting antivirals used in interferon-free
regimens can now cure most people with chronic hepatitis C virus, including
people who were previously considered difficult to treat, such as those with
genotype 3, advanced liver or kidney disease, or HIV/HCV co-infection.
AbbVie's Maviret (marketed as Mavyret
in the US), which was approved in August, contains the HCV NS3/4A protease
inhibitor glecaprevir and the NS5A inhibitor pibrentasvir. Both drugs are
pangenotypic, meaning they are active against all HCV genotypes.